Pharming Group (PHGUF)
(Delayed Data from OTC)
$0.76 USD
-0.04 (-5.13%)
Updated Aug 2, 2024 10:25 AM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Pharming Group NV falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 213 | 208 | 192 | 192 | 74 |
Receivables | 46 | 28 | 30 | 33 | 29 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 57 | 42 | 27 | 20 | 16 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 316 | 278 | 249 | 245 | 119 |
Net Property & Equipment | 10 | 10 | 13 | 11 | 10 |
Investments & Advances | 10 | 10 | 9 | 7 | 6 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 30 | 23 | 21 | 30 | 32 |
Intangibles | 71 | 75 | 84 | 88 | 79 |
Deposits & Other Assets | 2 | 1 | 1 | 0 | 3 |
Total Assets | 463 | 426 | 397 | 389 | 256 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 73 | 54 | 42 | 44 | 41 |
Current Portion Long-Term Debt | 2 | 2 | 2 | 2 | 51 |
Current Portion Capital Leases | 4 | 3 | 2 | 2 | 2 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 23 | 20 |
Total Current Liabilities | 78 | 60 | 47 | 71 | 114 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 137 | 132 | 139 | 139 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 30 | 30 | 18 | 8 | 5 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 19 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 244 | 221 | 204 | 219 | 138 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 8 | 8 | 7 | 7 | 7 |
Capital Surplus | 478 | 462 | 455 | 453 | 439 |
Retained Earnings | -265 | -256 | -273 | -295 | -333 |
Other Equity | -2 | -9 | 3 | 5 | 4 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 219 | 205 | 193 | 171 | 117 |
Total Liabilities & Shareholder's Equity | 463 | 426 | 397 | 389 | 256 |
Total Common Equity | 219 | 205 | 193 | 171 | 117 |
Shares Outstanding | 652.40 | 652.40 | 625.80 | 625.80 | 625.80 |
Book Value Per Share | 0.34 | 0.31 | 0.31 | 0.27 | 0.19 |
Fiscal Year End for Pharming Group NV falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 202 | 213 | 198 | -99,999 |
Receivables | NA | 39 | 46 | 41 | NA |
Notes Receivable | NA | 0 | 0 | NA | NA |
Inventories | NA | 56 | 57 | 53 | NA |
Other Current Assets | NA | 0 | 0 | NA | NA |
Total Current Assets | NA | 297 | 316 | 292 | NA |
Net Property & Equipment | NA | 9 | 10 | 10 | NA |
Investments & Advances | NA | 8 | 10 | 9 | NA |
Other Non-Current Assets | NA | 0 | 0 | NA | NA |
Deferred Charges | NA | 36 | 30 | 27 | NA |
Intangibles | NA | 68 | 71 | 70 | NA |
Deposits & Other Assets | NA | 2 | 2 | 2 | NA |
Total Assets | NA | 442 | 463 | 436 | NA |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | NA | NA |
Accounts Payable | NA | 69 | 73 | 63 | NA |
Current Portion Long-Term Debt | NA | 135 | 2 | 2 | NA |
Current Portion Capital Leases | NA | 4 | 4 | 4 | NA |
Accrued Expenses | NA | 0 | 0 | NA | NA |
Income Taxes Payable | NA | 0 | 0 | NA | NA |
Other Current Liabilities | NA | 0 | 0 | NA | NA |
Total Current Liabilities | NA | 207 | 78 | 68 | NA |
Mortgages | NA | 0 | 0 | NA | NA |
Deferred Taxes/Income | NA | 0 | 0 | NA | NA |
Convertible Debt | NA | 0 | 137 | 130 | NA |
Long-Term Debt | NA | 0 | 0 | NA | NA |
Non-Current Capital Leases | NA | 28 | 30 | 29 | NA |
Other Non-Current Liabilities | NA | 0 | NA | NA | |
Minority Interest (Liabilities) | NA | 0 | 0 | NA | NA |
Total Liabilities | NA | 236 | 244 | 227 | NA |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | NA | NA |
Common Stock (Par) | NA | 8 | 8 | 8 | NA |
Capital Surplus | NA | 480 | 478 | 476 | NA |
Retained Earnings | NA | -277 | -265 | -263 | NA |
Other Equity | NA | -4 | -2 | -11 | NA |
Treasury Stock | NA | 0 | 0 | NA | NA |
Total Shareholder's Equity | NA | 206 | 219 | 210 | NA |
Total Liabilities & Shareholder's Equity | NA | 442 | 463 | 436 | NA |
Total Common Equity | 0 | 206 | 219 | 100,209 | 0 |
Shares Outstanding | 652.40 | 652.40 | 652.40 | 652.40 | 652.40 |
Book Value Per Share | 0.00 | 0.32 | 0.34 | 153.60 | 0.00 |